Bristol Myers Squibb has opted to buy the global rights to Prothena’s anti-tau Alzheimer’s candidate PRX005, paying $55m to expand an existing US-only deal.
There have been scores of failed tau-targeting candidates over the last two decades, but enhanced understanding of how to target...